Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:
Osteogenesis imperfecta, or OI, is a group of genetic disorders characterized by decreased bone mass and increased bone fragility. Ultragenyx is developing an antibody treatment for the disease called setrusumab that works by blocking sclerostin, a protein that inhibits bone formation. An interim analysis of a Phase 3 study evaluating the ability of setrusumab to reduce bone fractures in patients with OI is expected early this quarter.
Praxis Precision Medicines is developing a drug called ulixacaltamide for essential tremor, a neurological disease that causes involuntary shaking of the limbs. A pre-planned interim analysis of a Phase 3 study will be reported this quarter.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in